Jasper Therapeutics, Inc. JSPR 深 沪
已收盘 02-06 16:00:00 美东时间
1.35
+0.080
+6.30%
华盛通- 最 高1.41
- 今 开1.30
- 成交量 52.68万股
- 最 低 1.2828
- 昨 收 1.27
- 总市值 3777.85万
- 52周最高 7.19
- 市盈率 静 --
- 换手率 1.88%
- 52周最低 1.26
- 委 比 45.59%
- 总股本 2798.40万
- 历史最高 188.80
- 量 比 1.15
- 振 幅 10.02%
- 历史最低 1.26
- 每 手 1
- 风险率 1.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jasper Therapeutics Reports Updated Clinical Data From BEACON Phase 1b/2a Study Of Subcutaneous Briquilimab In Adult Participants With CSU, As Well As From Open Label Extension Study In CSU And CIndU
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension
01-08 20:09
Jasper Stock Jumps After Promising New Asthma Study Results
Jasper Therapeutics released positive data from a study of subcutaneous briquilimab for allergic asthma treatment.
2025-12-03 00:14
Market-Moving News for December 2nd
MDB: 24% | MongoDB shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY26 guidance above estimates. Also, the company issued Q4 guidance above
2025-12-02 20:12
JSPR shares are trading lower after the company scheduled an investor webinar to present preliminary ETESIAN asthma study data and BEACON study findings.
JSPR shares are trading lower after the company scheduled an investor webinar t...
2025-12-02 05:32
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $4
RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Perform and lowers the price target from $5 to $4.
2025-11-11 23:25
CoreWeave Bulls Should Brace For 'Wild, Lumpy, Volatile Ride,' JPMorgan Says
JPMorgan downgrades CoreWeave, citing turbulence in AI infrastructure market. Despite near-term challenges, long-term growth...
2025-11-11 22:03
Jasper Therapeutics Q3 EPS $(1.13) Beats $(1.28) Estimate
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.28) by 12.06 percent. This is a 8.87 percent increase over losses of $(1.24) per share
2025-11-10 21:05
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or...
2025-10-11 08:05
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
2025-09-23 09:52
